Literature DB >> 12042230

Thioridazine and sudden unexplained death in psychiatric in-patients.

J G Reilly1, S A Ayis, I N Ferrier, S J Jones, S H L Thomas.   

Abstract

BACKGROUND: Sudden death has been linked to antipsychotic therapy, but the relative risk associated with specific drugs is unknown. AIMS: To assess the risk of sudden unexplained death associated with antipsychotic drug therapy and its relation to drug dose and individual agents.
METHOD: A case-control study of psychiatric in-patients dying suddenly in five hospitals in the north-east of England and surviving controls matched for age, gender and mental disorder. Logistic regression analysis was used to identify significant risk factors, and odds ratios were calculated.
RESULTS: Sixty-nine case-control clusters were identified. Probable sudden unexplained death was significantly associated with hypertension, ischaemic heart disease and current treatment with thioridazine (adjusted odds ratio=5.3, 95% CI 1.7-16.2, P=0.004). There was no significant association with other individual antipsychotic drugs.
CONCLUSIONS: Thioridazine alone was associated with sudden unexplained death, the likely mechanism being drug-induced arrhythmia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12042230     DOI: 10.1192/bjp.180.6.515

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  31 in total

1.  Response of i(kr) and HERG currents to the antipsychotics tiapride and sulpiride.

Authors:  Su-Hyun Jo; So-Young Lee
Journal:  Korean J Physiol Pharmacol       Date:  2010-10-31       Impact factor: 2.016

Review 2.  Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

Authors:  Marc De Hert; Johan Detraux; Ruud van Winkel; Weiping Yu; Christoph U Correll
Journal:  Nat Rev Endocrinol       Date:  2011-10-18       Impact factor: 43.330

3.  Antipsychotics and the Risks of Sudden Cardiac Death and All-Cause Death: Cohort Studies in Medicaid and Dually-Eligible Medicaid-Medicare Beneficiaries of Five States.

Authors:  Charles E Leonard; Cristin P Freeman; Craig W Newcomb; Warren B Bilker; Stephen E Kimmel; Brian L Strom; Sean Hennessy
Journal:  J Clin Exp Cardiolog       Date:  2013

Review 4.  Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death.

Authors:  Karine Titier; Pierre-Olivier Girodet; Hélène Verdoux; Mathieu Molimard; Bernard Bégaud; Wilhelm Haverkamp; Malcolm Lader; Nicholas Moore
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

5.  In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs.

Authors:  Marie L De Bruin; Pim N J Langendijk; Richard P Koopmans; Arthur A M Wilde; Hubert G M Leufkens; Arno W Hoes
Journal:  Br J Clin Pharmacol       Date:  2006-07-21       Impact factor: 4.335

Review 6.  Psychotropic medication use for behavioral symptoms of dementia.

Authors:  Philip S Wang; M Alan Brookhart; Soko Setoguchi; Amanda R Patrick; Sebastian Schneeweiss
Journal:  Curr Neurol Neurosci Rep       Date:  2006-11       Impact factor: 5.081

7.  QT prolongation and Torsades de Pointes following overdose of ziprasidone and amantadine.

Authors:  Alex F Manini; Dara Raspberry; Robert S Hoffman; Lewis S Nelson
Journal:  J Med Toxicol       Date:  2007-12

Review 8.  Are the safety profiles of antipsychotic drugs used in dementia the same? An updated review of observational studies.

Authors:  Gianluca Trifiró; Janet Sultana; Edoardo Spina
Journal:  Drug Saf       Date:  2014-07       Impact factor: 5.606

9.  Factors associated with the prescribing of olanzapine, quetiapine, and risperidone in patients with bipolar and related affective disorders.

Authors:  Maithri Prabhakar; William G Haynes; William H Coryell; Elizabeth A Chrischilles; Del D Miller; Stephan Arndt; Vicki L Ellingrod; Lois Warren; Jess G Fiedorowicz
Journal:  Pharmacotherapy       Date:  2011-08       Impact factor: 4.705

Review 10.  Thioridazine: resurrection as an antimicrobial agent?

Authors:  H K R Thanacoody
Journal:  Br J Clin Pharmacol       Date:  2007-08-31       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.